{"id":192134,"date":"2026-08-10T10:45:15","date_gmt":"2026-08-10T05:15:15","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=192134"},"modified":"2026-08-10T10:45:16","modified_gmt":"2026-08-10T05:15:16","slug":"divis-laboratories-vs-laurus-labs-comparison","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/divis-laboratories-vs-laurus-labs-comparison\/","title":{"rendered":"Divi’s Laboratories vs Laurus Labs: Which Stock Should You Track"},"content":{"rendered":"
<\/div>\n

Divi’s Labs MCap Rs 2,21,666 Cr, PE 75.79x, ROE 15.32%, zero debt, Div 0.36%. Laurus Labs MCap Rs 99,563 Cr, PE 91.31x, ROE 16.77%, D\/E 0.48.<\/em><\/p>\n

Divi’s Laboratories vs Laurus Labs is a comparison pharma API investors look up when evaluating two of India’s leading active pharmaceutical ingredient makers. Divi’s Laboratories is one of the world’s largest custom API manufacturers with a dominant share in select molecules for global innovators, while Laurus Labs is a high-growth API company with specialisation in ARV (antiretroviral) APIs, oncology APIs and a growing formulations business. Both are key suppliers to global generic and innovator pharma companies.<\/p>\n

This Divi’s Laboratories vs Laurus Labs article covers reach and market position, key products, latest declared results and stock valuation. The Divi’s Laboratories vs Laurus Labs data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n